Eight companies added themselves to the IPO runway:
-- Adnexus Therapeutics, which is focused on discovering, developing, and
commercializing the proprietary drug class called Adnectins. Adnexus'
first product candidate, Angiocept (CT-322), is in Phase 1 clinical
development in oncology in the United States. Adnectins are designed
and optimized using PROfusion, the company's patented protein design
engine that enables rapid optimization of protein therapeutics.
-- Anacor Pharmaceuticals, which is developing novel small-molecule
therapeutics derived from boron chemistry. The company has focused
initially on developing topical applications of its compounds to treat
fungal, bacterial and inflammatory diseases and its most advanced
product candidate is AN2690, a topical antifungal in development for
the treatment of toenail onychomycosis, which is a fungal infection of
the nail and nail bed.
-- ARYx Therapeutics, focuses on discovering and developing product
candidates designed to eliminate known safety issues associated with
commercially successful drugs,
-- Biolex Therapeutics is developing recombinant human therapeutic
proteins and monoclonal antibodies that, until now, have been
impossible or very expensive to develop in existing protein expression
-- Genoptix, Inc., a certified laboratory headquartered in Carlsbad,
California, provides personalized medicine services to hematologists
and oncologists that combine proprietary and exclusive tests with
advanced clinical techniques for comprehensive evaluation of individual
-- Insys Therapeutics, which focuses on discovering, developing and'/>"/>
|SOURCE Burrill & Company|
Copyright©2007 PR Newswire.
All rights reserved